

DRIEHAUS CAPITAL MANAGEMENT LLCDriehaus Event Driven Fund Portfolio
as of 3/31/2018**Security Name**

ACLARIS THERAPEUTICS	COM
ADVERUM BIOTECH INC	
ALTICE NV	EUR0.01 (COMMON SHAR
ALTICE USA INC	CL A
ARCUS BIOSCIENCES IN	COM
ARRAY BIOPHARMA INC	COM
ATARA BIOTHERAPEUTIC	COM
AVAYA HLDGS CORP	COM
BLUEPRINT MEDICINES	COM
BUILDERS FIRSTSOURCE	COM
CLEMENTIA PHARMACEUT	COM
CONCERT PHARMACEUTIC	COM
CONSOLIDATED COMMUNI	6.5000% 10/01/22
EAGLE MATERIALS INC	
EUR FORWARD	CONTRACT 05/07/2018
EXTENDED STAY AMER I	SHS 1 COM 1 CL B
FGL HOLDINGS	
GENERAL MTRS CORP	DEB SR CV C ESCROW
GENERAL MTRS CORP	DEB SR CONV B ESCROW
GETTY IMAGES	BANK LOAN 10/18/2019
GETTY IMAGES INC	7.00% 10/15/2020
GREAT BRITAIN POUND	
HC2 HLDGS INC	11.0000% 12/01/19
HC2 HOLDINGS INC	
HUNTSMAN CORP	
IDEAYA BIOSCIENCES,	INC. PRIVATE EQUITY
INVUITY INC	COM NEW
ISHARES NASDAQ	BIOTECHNOLOGY ETF
KNIGHT SWIFT	TRANSPORTATION HLD
LOXO ONCOLOGY INC	COM
MARTIN MARIETTA	MATERIALS
MARVELL TECHNOLOGY	GROUP LTD
MON 07/20/18 C120	MONSANTO CO NEW
MON 07/20/18 C125	MONSANTO CO NEW
MON 07/20/18 P105	MONSANTO CO NEW
NATERA INC	COM
NUVECTRA CORP	COM
NXP SEMICONDUCTORS N	COM
NXPI 01/18/19 C110	NXP SEMICONDUCTORS N
OCEANFIRST FINL CORP	COM
ORITANI FINANCIAL	CORP
QUANTA SERVICES INC	
RENT A CTR INC NEW	4.7500% 05/01/21
RENT-A-CENTER INC	
ROCKWELL COLLINS	INC.
SIERRA ONCOLOGY INC	COM
SPDR SERIES TRUST	S&P BIOTECH

USB REALTY CORP
UTX 01/18/19 C135
VENATOR MATLS PLC
WATERSTONE FINANCIAL
XPO LOGISTICS INC

VAR RT PERPETUAL
UNITED TECHNOLOGIES
SHS
COM

Source: Driehaus Capital Management LLC

The portfolio represents holdings for the Driehaus Event Driven Fund (the "Fund") as of the specified date. The Fund assumes no obligation to update or supplement the holdings to reflect subsequent changes. The holdings posted may not represent current or future portfolio composition or holdings and are subject to change without notice. Information on particular holdings may be withheld if it is in the Fund's best interest to do so. The holdings are unaudited and are provided for general information on the Fund. For more information please contact us at 877-779-0079. For information regarding the Fund's policy for valuation of investments and other significant accounting policies, please refer to the Fund's recent Semi-Annual or Annual financial statements.